Clinical trials investigating mebendazole in pediatric brain tumors:
I found that two primary clinical trials have been registered on ClinicalTrials.gov specifically evaluating mebendazole in pediatric brain tumor populations:
NCT02644291 (sponsored by Johns Hopkins) and NCT01837862 (sponsored by Cohen Children’s Medical Center / Northwell Health). Both studies have completed their Phase 1 dose-escalation evaluations in children and young adults (ages 1–21) with refractory, recurrent, or progressive high-grade gliomas, medulloblastoma, and diffuse midline gliomas.
Key themes:
Registry Numbers & Current Status: NCT02644291 (”Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors”) is listed as Completed, and NCT01837862 (”A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas”) has completed its intervention phase with findings published in pediatric neuro-oncology literature.
Trial Locations: Participating centers include the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Baltimore, MD), Johns Hopkins All Children’s Hospital (St. Petersburg, FL), Cohen Children’s Medical Center of New York (New Hyde Park, NY), and Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center (Hackensack, NJ).
Safety and Maximum Dosing: Pediatric trials demonstrated that oral mebendazole is safe and well tolerated in children at escalating doses up to 200 mg/kg/day (administered as chewable tablets), with no dose-limiting toxicities and toxicities restricted primarily to manageable hematologic events (neutropenia and lymphopenia).
Preliminary Antitumor Activity: In NCT01837862, when mebendazole was combined with bevacizumab and irinotecan in children with high-grade gliomas and diffuse midline gliomas, investigators reported an overall response rate of 33% (including one complete response sustained for 10 months and two partial responses).


